Yükleniyor... / Loading...
This study evaluated the safety and efficacy of Meplazumab injection compared with saline in people with ongoing post-COVID-19 symptoms. It enrolled patients aged 18-84 who had at least one post-COVID-19 symptom such as insomnia, fatigue, or changes in smell or taste. It was conducted in Phase 3 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: 1. Age 18 to 84 (including 18 and 84), male and female 2. Patients had been infected with 2019-ncov and had at least one symptom of Post-COVID-19 after infection, such as insomnia, memory loss, smell change, taste change, fatigue or fatigue, headache, chest pain, muscle/joint pain, shortness of breath, cough, palpitation, arrhythmia, and aggravation of the primary disease 3. According to the Post-COVID-19 Clinical symptom assessment form , the total symptom assessment score of the subjects was ≥2 before randomization 4. Agree to use highly effective birth control within 3 months of using the experimental drug 5. The subjects were able to communicate well with the investigators, understand and comply with the requirements of the study, and understand and sign the informed consent Exclusion Criteria: 1\. Patients with allergic constitution and known allergic to the test drug and its components 2\. Patients who underwent surgery or chemotherapy or radiotherapy within 28 days before screening 3\. Patients had a serious systemic disease, condition, or disorder, etc., that was deemed by the investigator to be inappropriate for participation in the study 4\. Use of an anti-coronavirus treatment such as Paxlovid (nematavir/ritonavir packaged in combination) within three half-lives before the first dose or during the study period, About 18 h at t1/2), Azvudine tablets (about 9 h at t1/2), and monolavir capsules (about 3.3 h at t1/2) h), ambavirumab/romisivir injection (t1/2 about 45 days /75 days), COVID-19 human immunoglobulin (t1/2 about 3-4 weeks) or recovery plasma (t1/2 about 21 days), deuremidvir hydrobromide tablets (t1/2 about 4.80-6.95 hours), etc 5\. At the time of screening, any of the laboratory test indicators meet the following criteria 1. ALT or AST \>3ULN 2. Total bilirubin ≥2 ULN 3. White blood cell count \> 2 ULN 4. Neutrophil absolute value\<0.5×109/L 5. Platelet count \< 80×109/L 6. eGFR \<60 mL/min/1.73 m2 (calculated by CKD-EPI formula) Note: For patients with connective tissue diseases such as systemic lupus erythematosus, Sjogren's syndrome, and inflammatory myopathy, including but not limited to the above three diseases, the value of this index was determined by the investigator 6\. Weight ≤40 kg 7\. Dizzy with needles and blood 8\. Had participated in other drug clinical trials within 3 months before screening 9\. Pregnant, lactating women or those with a positive pregnancy 10\. Other factors that the investigators considered inappropriate for trial entry